文献速递重症综合管理与镇静镇痛

重症监护中使用选择性5-羟色胺再摄取抑制剂与5-羟色胺-去甲肾上腺素再摄取抑制剂的系统评价:获益或危害的证据

Using Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in Critical Care: A Systematic Review of the Evidence for Benefit or Harm.
PubMed 文献 · Crit Care Med · 2017-01-01
一句话结论系统评价提示ICU中SSRI/SNRI使用者可能存在过多的并发症,但不确定是慢性效应、持续用药还是撤药所致,需改进用药报告标准后进一步研究。

该系统评价检索1990年至2014年11月Medline、Embase和Cochrane数据库,纳入ICU入住前或期间有SSRI/SNRI处方记录并报告发病率、死亡率、不良事件或资源利用指标的研究,排除故意过量服药和非ICU抑郁症研究。共纳入13项研究、20,048例患者,包括5项队列研究、1项病例系列和7项病例报告。仅1项病例报告提示使用SSRI/SNRI有获益,11项研究报告了入住ICU时使用这些药物患者的发病率。但由于药物给药报告不充分,通常不清楚门诊SSRI/SNRI是否在ICU继续使用,使解读复杂化。结论认为危重SSRI/SNRI使用者可能存在过多的并发症,但不确定是慢性效应、持续使用还是撤药所致,需进一步研究以帮助临床医生决定何时在危重患者中使用SSRI/SNRI。

要点

  • 13项研究共20,048例患者中,11项报告了入住ICU时使用SSRI/SNRI患者的发病率,仅1项病例报告提示获益。
  • 由于药物给药报告不充分,通常不清楚门诊SSRI/SNRI是否在ICU继续使用,使并发症归因于慢性效应、持续用药还是撤药变得困难。
  • 系统评价结论提示危重SSRI/SNRI使用者可能存在过多的并发症,但不确定性仍存。
  • 作者认为需要进一步研究并改进药物给药报告标准,以帮助临床医生决定何时在危重患者中使用SSRI/SNRI。

适用人群与场景

  • ICU患者,入住前或入住期间有SSRI/SNRI处方记录。
  • 排除故意过量服药的研究和非ICU环境中抑郁症的研究。

研究设计与关键结果

  • 系统评价检索到4,172条唯一引文,其中289篇全文审查,最终13项研究共20,048例患者符合纳入标准。
  • 纳入研究包括5项队列研究、1项病例系列和7项病例报告。
  • 仅1项病例报告提示使用SSRI/SNRI有获益。
  • 11项研究报告了入住ICU时使用这些药物患者的发病率。

证据类型、等级与局限

  • 证据类型:系统评价,纳入队列研究、病例系列和病例报告。
  • 由于药物给药报告不充分,通常不清楚门诊SSRI/SNRI是否在ICU继续使用,使解读复杂化。
  • 作者结论提示危重SSRI/SNRI使用者可能存在过多的并发症,但不确定是慢性效应、持续使用还是撤药所致。
  • 作者认为需要进一步研究并改进药物给药报告标准,以帮助临床医生决定何时在危重患者中使用SSRI/SNRI。

对床旁实践的改变

  • 作者认为危重SSRI/SNRI使用者可能存在过多的并发症,临床医生应关注这一人群的并发症风险。
  • 作者认为需要进一步研究以帮助临床医生决定何时在危重患者中使用SSRI/SNRI。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors are among the most commonly prescribed drugs in patients admitted to the ICU. Our objective was to systematically review available literature for evidence of benefit or harm in ICU patients resulting from chronic effects, continued use, or withdrawal.

DATA SOURCES: Medline, Embase, and Cochrane Central Register of Controlled Trials (1990 to November 2014).

STUDY SELECTION: We searched for studies of ICU patients with recorded selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor prescription before or during admission, and reporting morbidity, mortality, adverse events, and resource measures like ICU length of stay. We considered all study designs. We excluded studies of deliberate overdose and depression in non-ICU settings. Two authors independently and in duplicate screened citations and reviewed text of studies to apply selection criteria.

DATA EXTRACTION: Two authors abstracted data on patient characteristics in exposed and control groups; use of selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors previously or during ICU; comparator intervention; and outcomes, and also assessed methodologic quality.

DATA SYNTHESIS: The database search retrieved 4,172 unique citations, of which 289 were reviewed, and 13 studies representing a total of 20,048 patients met selection criteria. There were five cohort studies, one case series, and seven case reports. Only one case report suggested benefit from selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor use and 11 studies reported morbidity in patients using these medications at admission to ICU. However, due to inadequate drug administration reporting, it was generally unclear if outpatient selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors were continued in ICU, complicating interpretation.

CONCLUSIONS: There may be excess morbidity in critically ill selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor users, but uncertainty remains whether this is due to chronic effects, ongoing use, or drug withdrawal. Further research with improved standards of drug administration reporting is needed to help clinicians decide when to use selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors in critically ill patients.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Kelly JM, Rubenfeld GD, Masson N, et al. Using Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in Critical Care: A Systematic Review of the Evidence for Benefit or Harm. Crit Care Med. 2017. PMID: 28338497. doi:10.1097/CCM.0000000000002308

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。